Evidence of survival benefit was often ambiguous in randomized trials of cancer treatments

Perneger, Thomas; Brindel, Pauline; Combescure, Christophe; Gayet-Ageron, Angèle

doi:10.1016/j.jclinepi.2020.06.026

Scientific article

English

Evidence of survival benefit was often ambiguous in randomized trials of cancer treatments

ContributorsPerneger, Thomas; Brindel, Pauline; Combescure, Christophe

; Gayet-Ageron, Angèle

Published inJournal of Clinical Epidemiology, vol. 127, p. 1-8

Publication date2020

Abstract

The objective of the study is to estimate the proportion of statistically significant survival improvements reported in randomized trials of cancer treatments that are also compatible with a clinically negligible benefit.

Keywords

Confidence Intervals
Cross-Sectional Studies
Data Interpretation, Statistical
Humans
Neoplasms/drug therapy/mortality/radiotherapy
Periodicals as Topic/statistics & numerical data
Probability
Randomized Controlled Trials as Topic/statistics & numerical data
Treatment Outcome
Uncertainty

Affiliation entities

Research groups

Epidémiologie clinique et biostatistique (115)

Citation (ISO format)

PERNEGER, Thomas et al. Evidence of survival benefit was often ambiguous in randomized trials of cancer treatments. In: Journal of Clinical Epidemiology, 2020, vol. 127, p. 1–8. doi: 10.1016/j.jclinepi.2020.06.026

Article (Published version)

CC BY-NC-ND

Identifiers

PID : unige:151658
DOI : 10.1016/j.jclinepi.2020.06.026
PMID : 32622900

Journal ISSN0895-4356

156views

85downloads

Creation05/03/2021 6:55:00 PM

First validation05/03/2021 6:55:00 PM

Update time03/16/2023 12:34:37 AM

Status update03/16/2023 12:34:35 AM

Last indexation10/31/2024 10:05:47 PM

Archive ouverte UNIGE

Evidence of survival benefit was often ambiguous in randomized trials of cancer treatments

The objective of the study is to estimate the proportion of statistically significant survival improvements reported in randomized trials of cancer treatments that are also compatible with a clinically negligible benefit.

Technical informations